Targeting AURKA activation using inhibitors like MLN8237 (Alisertib) in pancreatic cancers (PancT4 cell line and Primary cells from tumors) suppresses tumor formation (Neel et al., 2014). The gene discussed is AURKA; the disease is familial pancreatic carcinoma.